Navigation Links
Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Date:4/6/2009

COSTA MESA, Calif., April 6 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced today that company Chairman and CEO, Chris Stern, has posted a new entry on his blog on the company website. The latest blog discusses the company's recent meetings in Zurich, Switzerland, further development plans for Oxycyte(R) in indications beyond traumatic brain injury, supply plans for clinical-grade Oxycyte, and plans for raising additional capital.

The blog is available on the company's Electronic Shareholder Forum which can be found via the Investor Relations page of the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
2. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
3. Oxygen Biotherapeutics, Inc. Expands Board of Directors
4. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
5. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
6. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
7. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
8. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
9. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
10. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)... Dec. 17, 2014   Synageva BioPharma Corp. ... therapeutic products for rare disorders, announced today its presentation ... in San Francisco, CA. ... Executive Officer, will present on Monday, January 12, 2015, ... will be webcast live and may be accessed from ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... chimp? Researchers from the European Molecular Biology Laboratory,s ... step closer to answering such evolutionary questions correctly. ... they uncover systematic errors in existing methods that ... about their evolutionary relationships. They present a new ...
... the Northeast Ohio,venture development organization that accelerates ... has announced an investment commitment of,$350,000 in ... part of a recently closed investment round ... Cleveland, OH., (Logo: http://www.newscom.com/cgi-bin/prnh/20060209/CLJUMPSTARTLOGO ...
... Calif., June 19 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... the Jefferies 2nd Annual Healthcare Conference on Thursday, ... may access a live webcast of,the presentation on ... It is recommended that listeners log on 15 ...
Cached Biology Technology:Scientists fix bugs in our understanding of evolution 2JumpStart Invests in Tursiop Technologies 2JumpStart Invests in Tursiop Technologies 3
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/10/2014)... pods began appearing on U.S. store shelves in early ... ever since. The small packets can be tossed into ... a liquid or powder. The convenience, though, has come ... from researchers at Nationwide Children,s Hospital found that from ... of 17,230 children younger than 6 years of age ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2
... plant will flower, what soil type is best or its ... ability of plants to adapt to new environments. This type ... to human well being. An international collaboration of researchers, ... genetic data from 19 different strains of a humble plant ...
... cells is usually achieved through the accumulation of glucose, in ... But when this accumulation happens in neurons it is fatal, ... with glycogen accumulation is the hallmark of an extremely rare ... The journal EMBO Molecular Medicine has ...
... looking to a virus from the same family as the ... in children and young adults. They report their findings ... Virology. Soft tissue sarcomas are cancers that develop ... organs of the body. Muscles, tendons, fibrous tissues, fat, blood ...
Cached Biology News:Little plant tells big stories 2A mouse model brings new perspectives on Lafora disease 2Virus attacks childhood cancers 2
... uses include large-scale colony-counting and plaque-lifting, microbial ... TM automated colony picking and gridding ... product number, created to easily match Cornings ... please order under the old Sigma-Aldrich number ...
Mouse Anti-Human Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4 Monoclonal Antibody Family: New...
BD BioCoat Laminin 150 mm Culture Dishes...
...
Biology Products: